Background-Several epidemiological and clinical reports have suggested seropositivity for Helicobacter pylori may be a risk factor for coronary heart disease. However, there has been no prospective study of this association involving an ethnically diverse sample of middle-aged men and women. Methods and Results-Using a prospective, case-cohort design, we determined H pylori seropositivity in relation to coronary heart disease incidence over a median follow-up period of 3.3 years among middle-aged men and women. There were 217 incident coronary heart disease cases and a cohort sample of 498. We determined H pylori antibody status by measuring IgG antibody to the high-molecular-weight cell-associated proteins of H pylori using a sensitive and specific ELISA. The prevalence of H pylori seropositivity was higher in blacks than whites, in those with less than high school education, in those with lower plasma pyridoxal 5Ј-phosphate and higher homocyst(e)ine concentrations, in those who did not use vitamin supplements, in those with higher fibrinogen levels, and in those seropositive for cytomegalovirus and herpes simplex type I (all PϽ0.05). The age-, sex-, race-, and field center-adjusted hazard ratio of coronary heart disease for H pylori seropositivity was 1.03 (95% CIϭ0.68 to 1.57). After adjustment for other risk factors, including fibrinogen, cytomegalovirus seropositivity, and herpes simplex type I seropositivity, the hazard ratio was 0.85 (95% CIϭ0.43 to 1.69). H pylori seropositivity also was not associated with increased mean intima-media thickness of the carotid artery, a measure of subclinical atherosclerosis. Conclusions-H pylori infection is probably not an important contributor to clinical coronary heart disease events.
A lmost half of the adult population has serological evidence of infection with Helicobacter pylori, a contributor to gastritis, peptic ulcer, and gastric cancers. In 1994, Mendall and colleagues 1 reported that H pylori seropositivity was twice as common in coronary heart disease (CHD) patients as in control subjects. Danesh et al 2 recently reviewed 20 full or preliminary reports on H pylori and CHD published during 1994 to 1996. They concluded that evidence for a causal association between H pylori and CHD was weak because many of the studies were small, did not use population-based samples, and did not control well for confounding variables. Most of the better-designed studies had odds ratios close to 1.0.
Several mechanisms have been proposed for how H pylori might increase CHD risk. 2 For example, Patel et al [3] [4] [5] hypothesized that infection-related chronic inflammation from H pylori infection may increase CHD risk, because the CHD risk factors plasma fibrinogen, C-reactive protein, and blood leukocyte count have been elevated in seropositive subjects. Sung and Sanderson 6 hypothesized but offered no data to prove that H pylori gastritis could cause a B vitamin deficiency, leading to hyperhomocysteinemia and thus increased risk of CHD. H pylori also can stimulate leukocyte procoagulant activity. 7 However, 2 studies found no evidence of H pylori in the atherosclerotic plaques of abdominal aortic aneurysms 8 or carotid arteries 9 of patients who were seropositive for H pylori.
Only 4 prospective studies 10 -13 have examined whether H pylori seropositivity is associated with cardiovascular disease occurrence ( Table 1 ). The CIs of the estimated relative risks in these studies have all included 1.0. To provide an additional prospective test of the H pylori and CHD hypothesis, using a large and diverse sample of middleaged adults, we undertook a case-cohort analysis within the Atherosclerosis Risk In Communities (ARIC) study.
Methods

Study Population
The ARIC study 14 is a longitudinal epidemiological study of cardiovascular disease. In 1987 through 1989, we used driver's license lists or residential sampling to recruit a population-based cohort of persons aged 45 to 64 years from Forsyth County, North Carolina; Jackson, Miss (blacks only); the northwest suburbs of Minneapolis, Minn; and Washington County, Maryland. We included all ageeligible individuals within selected households and excluded only those who were institutionalized, had definite plans to move soon, or could not visit the ARIC clinic for physical or cognitive reasons. Approximately 46% of eligible individuals in Jackson and 65% in the other 3 communities completed a home interview and clinic examination, 15 yielding a total of 15 792 participants. We reexamined participants in 1990 to 1992 (93% of those still living returned for the examination) and in 1993 to 1995 (86% of the living returned). We also monitored the cohort for incident CHD events. All participants signed a consent form approved by human subjects research review committees at our institutions.
Baseline Measurements
Trained technicians measured blood pressure 3 times using a random-zero sphygmomanometer. We used the mean of the last 2 measurements for analysis. We expressed physical activity as a sport index ranging from 0 (low) to 5 (high). 16 Technicians measured circumferences of the waist (umbilical level). We computed body mass index (kg/m 2 ) from participants' weight and height in scrub suits. Technicians measured average carotid intima-media thickness using standardized B-mode ultrasonography. 17, 18 We defined prevalent CHD at baseline, for exclusion, as a reported history of a physician-diagnosed heart attack, prior myocardial infarction (MI) by ECG, prior cardiovascular surgery, or prior coronary angioplasty. ARIC also measured prior stroke or transient ischemic attack through a standardized interview.
Technicians drew fasting blood from an antecubital vein into vacuum tubes containing sodium citrate (hemostatic factors), EDTA (lipids, stored leukocytes), or a serum separator gel (glucose). They centrifuged the 2 anticoagulant tubes immediately, and the serum tube after clotting 30 to 45 minutes, at 3000g for 10 minutes at 4°C. They quickly froze aliquots at 70°C until analysis. Within a few weeks, ARIC investigators measured plasma fibrinogen, 19 total cholesterol, 20 triglycerides, 21 and HDL cholesterol 22 and calculated LDL cholesterol. 23 We measured serum glucose by the hexokinase method and defined diabetes as fasting glucose Ն140 mg/dL, nonfasting glucose Ն200 mg/dL, a physician diagnosis of diabetes, or pharmacological treatment for diabetes. Laboratories in each community counted leukocytes by automated cell counters.
Ascertainment and Classification of Incident CHD Cases
We monitored each participant and identified 24 and included for this analysis CHD events that occurred between ARIC visit 1 and December 31, 1991. The median follow-up time was 3.3 years (maximum 5.1 years). We defined CHD incidence as (1) a definite or probable MI, 24 (2) ECG evidence 25 of a silent MI between the first 2 ARIC examinations, (3) a definite CHD death, 24 or (4) a coronary revascularization.
Cohort Sample and Analysis of Stored Baseline Samples
We used a case-cohort design for this analysis in which H pylori antibody status was determined only for CHD cases and a stratified random sample of the ARIC cohort. We defined 8 strata for sampling the cohort, based on age (2 levels), sex, and carotid intima-media thickness (2 levels). We did this because other analyses on this sample also focused on comparing thick versus thin carotid artery walls. To account for the sampling design in analyses, we weighted each observation by the inverse of the sampling fraction, thereby recreating the original frequency distribution of the strata in the entire cohort.
In 1995, after ARIC had identified the incident cases and cohort sample, technicians pulled these participants' baseline samples, frozen in 1987 to 1989. The sera for this study had been thawed previously for other assays. We have considerable experience that shows that freeze-thawing up to 6 cycles does not affect H pylori antibody titers (D.Y.G., unpublished data, 1997). We measured IgG antibody to the high-molecular-weight cell-associated proteins of H pylori using an ELISA (HM-CAP, EPI) that has a sensitivity and specificity of Ն95%. 26 -28 There is no cross-reactivity with Campylobacter jejuni or other common human pathogens. On the basis of 33 random serum specimens that were split, masked, and analyzed for the present study, laboratory agreement on H pylori seropositivity (positive versus negative) was 88% (ie, 29 of 33 agreed). Two of the 4 disagreements were in the uncertain area of the assay (typically 2% are in this uncertain area).
We also measured antibodies to cytomegalovirus (CMV) and herpes simplex virus (HSV) type I 29, 30 and IgG titers to Chlamydia pneumoniae. 31, 32 We measured homocyst(e)ine using high-pressure liquid chromatography and electrochemical detection. [33] [34] [35] We measured plasma folate and vitamin B 12 by the Quantiphase II Radioassay (Bio-Rad Diagnostics Group) and pyridoxal 5Ј-phosphate using a radioenzymatic assay supplied by Bühlmann Laboratories AG through American Laboratory Products.
Data Analysis
Before analysis, we excluded participants identified as having prevalent CHD, stroke, or transient ischemic attack. We did not exclude 6.7% of participants who were positive for angina by the Rose questionnaire 36 (or for whom information to assess angina was missing) because the validity of the questionnaire, especially in women, has been questioned. 37 We also excluded 109 of 814 participants with missing H pylori antibody measurements because of insufficient sample. Those with antibody data present (nϭ705) versus missing were similar (PϾ0.05) on all but 3 of the characteristics in Table 2 . Blacks were less likely to have missing antibody measurements than were other participants (5% versus 16%); hypertensives were less likely than were normotensives (8% versus 15%); and those with carotid intima-media thickness Ն1 mm were less likely than were those with values Ͻ1 mm (0% versus 12%).
We first used logistic regression to compute the age-, race-, sex-, and field center-adjusted prevalence of H pylori seropositivity for CHD cases and noncases after appropriate weighting for the strati- 
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fied random sampling design and then computed a weighted average of these to get an estimate for the full cohort, weighting by the cohort disease probability. To determine the relation of seropositivity with other risk factors, we computed its prevalence according to categories of risk variables. We computed hazard ratios (HRs) and 95% CIs of CHD in relation to categories of study variables using a weighted proportional hazards regression, accounting for the case-cohort design and the stratified random sampling by Barlow's method. 38 This method weights each sampling stratum so that the estimated model coefficients approximate those that would have arisen from the full cohort and also accounts for the sampling scheme in computing the variance of the estimators of the coefficients. Covariates used in an initial model were age (continuous), sex, race (blacks, whites), and ARIC field center. We then adjusted for potentially confounding factors, that is, major risk factors or risk factors associated with H pylori antibody status: education (Ͻ high school graduate, Ն high school graduate), smoking status (never, former, current), vitamin supplementation (yes, no), total cholesterol (continuous), waist circumference (continuous), systolic blood pressure (continuous), and use of antihypertensive medication (yes, no). We then adjusted for factors that might be on the causal path between H pylori infection and CHD to determine if their inclusion was consistent with this possibility: fibrinogen (continuous), plasma pyridoxal 5Ј-phosphate (continuous), and homocyst(e)ine (continuous). Finally, to be sure any association for H pylori was not due to generally increased infection rates, we adjusted for 2 other markers of chronic infections potentially related to CHD in this cohort 30 : CMV seropositivity (yes, no) and HSV type I seropositivity (yes, no). We tested 4 hypothesized interactions (H pylori seropositivity by age, race, sex, and fibrinogen level) by entering cross product terms into the regression models.
Results
The sample included 217 incident CHD cases (27 fatal, 190 nonfatal) and a cohort stratified random sample of 498 (of whom 10 were also CHD cases). The age-, race-, sex-, and field center-adjusted prevalence of H pylori seropositivity was identical in CHD cases and the ARIC cohort itself (51%, Pϭ0.95).
As Table 2 shows, the prevalence of H pylori seropositivity was higher in blacks than whites, in those with less than high school education, in those with lower plasma pyridoxal 5Ј-phosphate and higher homocyst(e)ine concentrations, in nonusers of vitamin supplements, in those with higher fibrinogen levels, and in those who were seropositive for CMV and HSV type I (all PϽ0.05). When vitamin supplement users were excluded, H pylori seropositivity was still higher in those with homocyst(e)ine levels Ն15 versus Ͻ15 mol/L (79% versus 52%, Pϭ0.06) and in those with plasma pyridoxal 5Ј-phosphate Ͻ10 versus Ն10 nmol/L (75% versus 52%, Pϭ0.03). H pylori seropositivity was not statistically significantly associated with the other major CHD risk factors and specifically was not associated with baseline carotid intima-media thickness.
Adjusted for age, sex, race, and field center (Table 3) , the HR of CHD in relation to H pylori seropositivity (yes versus no) was 1.03 (95% CIϭ0.68 to 1.57). The HR for fatal CHD events was 1.42 (0.63 to 3.25). There was no statistically significant association when estimated separately for men (HRϭ0.92) or women (HRϭ1.26) or when estimated separately by age group (not shown) or race (HRϭ1.03 for both blacks and whites). Correspondingly, the tests of interactions of H pylori seropositivity by age, race, and sex were not significant. After additional adjustment for education level, smoking status, vitamin use, waist circumference, systolic blood pressure, and use of antihypertensive medications (Table 3) , CHD incidence was still not statistically significantly associated with H pylori seropositivity (HRϭ0.97, 95% CIϭ0.52 to 1.78). The covariate that reduced the HR the most (from 1.03 to 0.97) was smoking. Additional adjustment for factors potentially on the causal pathway [fibrinogen, plasma pyridoxal 5Ј-phosphate, and homocyst(e)ine] yielded an HR of 0.90 (95% CIϭ0.45 to 1.80). Of these added covariates, fibrinogen adjustment had the biggest impact on the HR. There was no evidence of a statistical interaction between fibrinogen and H pylori seropositivity in relation to CHD incidence. After further adjustment for CMV and HSV type I seropositivity, H pylori seropositivity was still not associated with CHD (HRϭ0.85, 95% CIϭ0.43 to 1.69).
Because our blind duplicate assessment suggested the measurement of H pylori status had a 12% misclassification rate (see Methods), we estimated the potential effect of this misclassification on the HR estimates. Assuming the misclassification was independent and random, 39 we estimated that the age-, race-, and sex-adjusted HR was biased toward the null value of 1.0 by Յ5%. Thus, laboratory measurement error does not seem to explain the lack of association between H pylori seropositivity and CHD incidence.
Discussion
We found little evidence in this prospective study that H pylori seropositivity was associated with CHD incidence. The overall HR after accounting for other CHD risk factors was 0.97, although the CI for this estimate was wide (between 0.52 and 1.78). H pylori seropositivity also was not materially associated with increased baseline carotid intima-media thickness, a measure of subclinical carotid atherosclerosis. Thus, despite suggestive evidence from some cross-sectional and clinical reports 1,2 and plausible mechanisms, 2-7 this and other prospective studies (Table 1) have failed to confirm an association of H pylori and CHD. The fact that studies of better design and more complete control of confounders do not find an independent association between H pylori and CHD suggests that bias may explain the positive reports. The higher H pylori seropositivity among blacks, those with less formal education, nonusers of vitamin supplements, and those seropositive for CMV and HSV type I is consistent with epidemiological studies showing that infection is higher in those who are socioeconomically disadvantaged. 40 -42 Higher seropositivity with lower plasma pyridoxal 5Ј-phosphate and higher homocyst(e)ine concentrations is partly consistent with Sung and Sanderson's hypothesis of H pylori gastritis causing a vitamin deficiency, 6 although it is not clear why there was not also an association with plasma folate and vitamin B 12 . The positive association of H pylori seropositivity with fibrinogen, reported previously 4, 42 but not uniformly, 13 ,42,43 may be the result of H pylori infection or confounding by the many other correlates of fibrinogen. 44 If H pylori infection indeed elevates fibrinogen, then statistical adjustment for fibrinogen would be overadjustment. However, we included fibrinogen in some regression models to see if it attenuated the HR, as would be expected from a factor in the causal path. It had a minor impact and did not alter the conclusion that H pylori was not appreciably associated with CHD in the cohort.
Some investigators have reported H pylori seropositivity may be increased in patients with diabetes. [45] [46] [47] However, our population-based results offer no evidence for this ( Table 2) .
Drawbacks of the present study are its relatively short follow-up (median of 3.3 years) and its inability to distinguish whether H pylori infection was current or only in the past. As a result, we may have missed an association between H pylori and CHD if it was very weak or if H pylori was involved primarily in early atherogenesis. This study nevertheless is one of the largest studies on H pylori and CHD to date and one of the few to include women and participants of African descent.
Although H pylori could still be a contributor to coronary atherosclerosis but not to acute coronary events, our study examining the carotid artery ultrasonographically and pathology studies of the aorta 8 and carotid 9 found no link between H pylori and atherosclerosis. Considering all available evidence, we agree with Danesh et al 2 that existing evidence suggests H pylori infection is probably not an important contributor to CHD.
